Kobieta w legginsach do ćwiczeń używająca różowej gumy oporowej podczas treningu w pomieszczeniu

GLP-1 Drugs and Muscle Mass Loss: What Do Body-Composition Studies Show?

Semaglutide and tirzepatide can reduce body weight by anywhere from the teens to the low twenties percent — a figure that dominates headlines. A second figure gets far less attention: what that lost weight is actually made of. DEXA body-composition studies show that part of it is lean body mass, including muscle — a phenomenon especially relevant for older patients and those who don't strength-train during treatment.

PZdr Piotr ZielińskiOctober 5, 202614 min read

Table of contents

TL;DR — key takeaways

→The number on the scale doesn't say what actually disappeared
→What the STEP 1 body-composition analysis showed (semaglutide)
→What the SURMOUNT-1 body-composition analysis showed (tirzepatide)
→Why this matters clinically, not just cosmetically
→What actually helps: resistance training and protein
→Does age and starting point matter
→Limitations of this evidence
→Our editorial recommendation

The number on the scale doesn't say what actually disappeared

GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) have revolutionized the pharmacological treatment of obesity, producing weight loss in registration trials on the order of the high teens to over twenty percent — a scale of effect previously unattainable without bariatric surgery. That figure, readily quoted in headlines, refers to total body weight on the bathroom scale, not to what it's actually made of.

Any significant body-weight reduction — regardless of method, whether a caloric deficit, diet, bariatric surgery, or a drug — involves not only fat tissue but also some loss of lean body mass, including muscle. This isn't a flaw specific to GLP-1 drugs but a physiological rule that applies to any significant weight loss. The question that actually matters clinically isn't 'does muscle loss happen,' but 'how large is it relative to fat loss, and can it be limited.'

What this article covers

This isn't an argument against using GLP-1 drugs — their effectiveness at reducing fat tissue is well documented. We focus on the other side of the ledger: what body-composition studies using DEXA actually show, who's at particular risk of muscle loss, and which strategies have real evidence behind them versus which are merely reasonable guesses.

What the STEP 1 body-composition analysis showed (semaglutide)

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study

Early-stage evidence

Wilding JPH, Batterham RL, Calanna S et al. · Journal of the Endocrine Society · 2021

An exploratory analysis of a STEP 1 subgroup with DEXA body-composition measurement (semaglutide n=95, placebo n=45). With a -15.0% body-weight change in the semaglutide group by week 68, total lean body mass decreased by -9.7% in absolute terms, while fat mass fell by -19.3% and visceral fat mass by -27.4%. Lean mass's share of total body mass actually rose slightly (+3.0 percentage points), because fat was lost proportionally faster.

View study

These numbers deserve careful interpretation. On one hand, fat was lost proportionally faster than muscle, which is a favorable direction for body composition. On the other hand, the loss of nearly 10% of lean body mass in absolute terms is real, measurable, and — with further, multi-year use of the drug — potentially clinically relevant, especially for people who entered treatment with little muscle reserve to begin with.

What the SURMOUNT-1 body-composition analysis showed (tirzepatide)

Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight

Moderate evidence

Look M, Dunn JP, Kushner RF et al. · Diabetes, Obesity and Metabolism · 2025

A DEXA analysis in a 160-person SURMOUNT-1 subgroup through week 72: body weight fell 21.3%, fat mass 33.9%, and lean body mass 10.9% with tirzepatide (versus -5.3%, -8.2%, and -2.6% with placebo). Of the weight lost, about 74% was fat tissue and 26% lean mass — a proportion similar across both the drug and placebo groups and to earlier semaglutide data.

View study

A surprising consistency across drugs and groups

Moderate evidence

The proportion of lost weight attributable to fat (about 74–75%) versus lean mass (about 25–26%) was similar regardless of whether participants took tirzepatide or were on placebo (i.e., lost weight mainly through the lifestyle intervention accompanying the trial). That's an important clue: the ratio of muscle to fat loss during significant weight reduction appears to be largely a physiological feature tied to the pace and scale of weight loss itself, rather than a specific, adverse effect of a particular drug.

In other words, it isn't that GLP-1 drugs 'eat muscle' in some way distinct from other weight-loss methods. The issue is rather the scale and speed of weight reduction these drugs make possible — someone losing 20% of body weight over a year and a half will, regardless of method, lose more muscle in absolute terms than someone losing 5% of the same body weight through diet alone.

Why this matters clinically, not just cosmetically

Muscle mass isn't just about physique aesthetics — it's a metabolically active tissue, key to resting metabolic rate, functional strength, bone density (through mechanical loading), and, in older adults, independence and fall risk. Muscle loss accompanying rapid weight reduction is especially relevant for two groups: older people, in whom the natural process of sarcopenia (progressive age-related loss of muscle mass and strength) is already underway independently of treatment, and people entering treatment with low baseline muscle mass, for example due to previous physical inactivity.

The phenomenon is gaining a name in the medical literature

Obesity pharmacotherapy literature increasingly uses the term 'sarcopenic obesity' in the context of rapid weight loss combined with insufficiently preserved muscle mass — a state in which apparent improvement (lower weight, lower BMI) doesn't fully translate into functional or metabolic improvement if a substantial share of the lost weight is muscle rather than fat.

On the other hand, it's worth keeping proportion: in both cited studies (STEP 1 and SURMOUNT-1), fat was lost noticeably faster than muscle, and lean mass's share of total body weight actually edged up slightly. This isn't, then, a scenario where a drug selectively 'eats' muscle while sparing fat — the direction of body-composition change is favorable; the question is rather how far it can still be optimized.

Check your profile

Not sure which supplements actually make sense for you?

Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.

Takes about 2 minutesBased on scientific evidence

Find supplements for me

Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.

What actually helps: resistance training and protein

Two interventions have the strongest evidence, independent of GLP-1 drugs specifically, for preserving muscle mass during weight loss: resistance (strength) training and increased dietary protein intake relative to reduced calories. The mechanism is simple and well understood — mechanical loading of muscle through strength training is an anabolic signal that, under a caloric deficit, helps the body prioritize preserving muscle tissue, while additional amino acids from protein supply the raw material for muscle protein synthesis even with limited total energy intake.

Myth

Strength training and higher protein intake during GLP-1 treatment are a tested, confirmed strategy specifically for these drugs, with dedicated RCTs of their own.

Fact

Dedicated, large RCTs testing resistance training and protein intake specifically in patients on semaglutide or tirzepatide remain scarce. This recommendation mostly extrapolates from solid data on preserving muscle mass during caloric deficit in other contexts (dietary weight loss, aging, rehabilitation) — logically sound, but not yet confirmed at the same evidentiary standard as the drugs' weight-loss efficacy itself.

Practical elements for limiting muscle loss during GLP-1 treatment

Regular resistance training (at least twice weekly, targeting major muscle groups) — the best-documented, though not specifically tested-on-this-drug-class, method of preserving muscle mass during a caloric deficit
Increased relative dietary protein intake (roughly 1.2–1.6 g per kilogram of body weight daily, to be confirmed individually with a dietitian), especially since reduced appetite on GLP-1 drugs can lead to insufficient protein intake along with an overall drop in food volume
Spreading protein across several meals a day, not just one large meal, which supports muscle protein synthesis throughout the day
Monitoring not just scale weight but, where possible, body composition too (e.g., bioimpedance, DEXA if accessible), to assess the ratio of fat to muscle loss rather than just the kilogram count
Discussing the pace of weight loss with a doctor or dietitian — very rapid weight loss is usually associated with proportionally greater muscle loss than slower, controlled reduction

Does age and starting point matter

The risk of clinically meaningful muscle-mass loss during GLP-1 treatment isn't spread evenly across the population. Older people, people with low physical activity before starting treatment, and people with already low baseline muscle mass (e.g., from prior sarcopenia or long-term lack of training) are in a group where a proportionally larger share of lost weight may fall on muscle, and the functional consequences of that loss are potentially more serious than for a younger, active person with well-developed muscle mass at the start.

Why older patients need particular attention

In older people, sarcopenia progresses independently of GLP-1 treatment, and additional, rapid muscle-mass loss caused by significant weight reduction may compound this process, increasing the risk of falls, functional weakness, and loss of independence — the metabolic benefits of rapid weight loss must be weighed against this risk in this group, ideally under the supervision of a geriatrician or a doctor experienced in this area.

Limitations of this evidence

What these studies don't prove

Both cited body-composition analyses (STEP 1 and SURMOUNT-1) are exploratory or post-hoc subgroup analyses, not the primary, pre-specified endpoints of the trials — the samples were relatively small (95–160 people) compared to the full registration-trial cohorts. Neither study directly tested a training or dietary intervention as a way to limit muscle loss — recommendations in this area are a reasonable extrapolation from other contexts, not the result of dedicated RCTs in this population. Long-term (beyond 2–3 years) body-composition data for extended use of these drugs remain limited.

Question	Short answer
Do GLP-1 drugs cause muscle loss?	Yes, in absolute terms (about 10% of lean body mass), but proportionally less than fat loss
Is this specific to these drugs?	Not fully — a similar ratio of fat to muscle loss was seen in placebo groups too
Do strength training and protein help?	Logically sound and widely recommended, but without dedicated large RCTs in this specific population
Who's at the greatest risk?	Older people, those less active before treatment, and those with low baseline muscle mass
Is this a reason to stop treatment?	Not on its own — it's an argument for monitoring body composition and providing training and dietary support during treatment

GLP-1 drugs and muscle mass loss at a glance

Our editorial recommendation

Muscle mass loss accompanying GLP-1 treatment isn't a reason for alarm, but it's a real, measurable phenomenon that deserves more attention than it gets in popular coverage of these drugs, which focuses almost exclusively on the number on the scale. DEXA data show a favorable direction of body-composition change — fat is lost faster than muscle — but not zero muscle loss, and practical training and dietary support remains a reasonable, if not yet fully independently tested, part of responsible treatment.

The number on the bathroom scale is just one digit in the whole story — what that number is actually made of decides whether treatment ends with better function, or just a lower number on the display.

Dr. Piotr Zieliński, VitMode editorial team

Frequently asked questions

Not to the same degree — the scale of loss depends on the pace and size of weight reduction, baseline muscle mass, age, and physical activity during treatment. DEXA analyses show losses on the order of 9–11% of lean body mass in absolute terms with significant weight reduction, but individual differences can be substantial.

Available DEXA data (STEP 1 for semaglutide, SURMOUNT-1 for tirzepatide) show a similar ratio of fat to lean-mass loss with both drugs — the difference mainly lies in tirzepatide's greater total weight reduction, which in absolute numbers also means greater absolute muscle loss, at a proportionally similar rate.

There's no single standard developed specifically for this drug class, but general guidance based on the broader literature on preserving muscle mass under a caloric deficit suggests 1.2–1.6 g of protein per kilogram of body weight daily — worth confirming a specific figure with a doctor or dietitian, especially since reduced appetite can make reaching that intake challenging.

Resistance (strength) training has the strongest evidence, though from other contexts, as a way to protect muscle mass during a caloric deficit — purely aerobic activity (e.g., just walking or cycling) doesn't provide the same anabolic signal for muscle, though it has other health benefits of its own.

It isn't a necessity for every patient, but it's the most accurate available method for distinguishing fat loss from muscle loss. Without DEXA access, simpler bioelectrical impedance gives a rough, less precise picture of body-composition changes over time.

Data on this are limited, but weight regain after stopping GLP-1 drugs (discussed more fully in our article on the yo-yo effect) is known to consist mainly of fat tissue, so it isn't a simple reversal of the earlier loss in the same proportion — which further underscores the importance of preserving muscle mass during treatment itself, rather than counting on rebuilding it afterward.

Not automatically — the metabolic and cardiovascular benefits of weight reduction can be significant in this group too, but the decision should factor in an individual assessment of sarcopenia risk, ideally involving a doctor familiar with geriatrics, and a clear plan for training and dietary support accompanying treatment from the start.

Sources

dr Piotr Zieliński

Specialist physician in endocrinology, scientific consultant

Piotr has practiced endocrinology for more than fifteen years, mostly in male hormonal disorders and metabolic health. He joined VitMode as a scientific consultant because, as he jokes, he got tired of explaining the same testosterone questions at every appointment and decided to write the answers down properly, once. He reviews content on hormone therapy, supplement pharmacology and drug interactions, making sure articles never turn into encouragement to self-supplement in situations that genuinely need diagnostics and medical supervision. His professional motto — "evidence first, enthusiasm second" — has come up more than once with a patient who arrived with a supplement plan they found online.

Retro waga z precyzyjną skalą i oznaczeniami liczbowymi

The Yo-Yo Effect After Stopping GLP-1 Drugs: What Does Extended Follow-Up Data Show?

Semaglutide and tirzepatide deliver spectacular weight-loss results — as long as they're used. Two independent extended-follow-up trials, one for semaglutide and one for tirzepatide, show what happens after stopping: most patients regain a significant portion of lost weight within a year, and the accompanying metabolic benefits partially reverse.

14 min

October 5, 2026

Wstrzykiwacz z semaglutydem stosowany w leczeniu cukrzycy

Semaglutide (Ozempic, Wegovy): What Do the Trials Actually Show About Side Effects?

Semaglutide, sold as Ozempic (diabetes) and Wegovy (weight loss), became within a few years one of the most prescribed and most talked-about drugs in the world. The promise — double-digit percentage weight loss without a restrictive diet — is backed by solid registration trials. Far less discussed is what those same trials showed on the other side of the ledger: who tolerates the drug poorly, what rare but serious complications large database analyses have flagged, and why part of the lost body weight isn't just fat.

14 min

September 4, 2026

HMB and Muscle Loss: When Does This Supplement Actually Make Sense?

HMB (β-hydroxy β-methylbutyrate), a leucine metabolite, is often marketed as a universal muscle-protecting supplement — for athletes building mass and seniors worried about sarcopenia alike. The research shows a clear split: in healthy, regularly training young adults the effect is negligible, while in strongly catabolic situations — immobilization, old age, illness — the evidence for muscle protection is considerably stronger. This distinction gets lost in most marketing material.

13 min

September 4, 2026

Naukowiec używający pipety do precyzyjnego dozowania płynu w laboratorium

Microdosing Ozempic: Is There Any Evidence Behind It?

On TikTok and at telehealth clinics, a promise circulates: semaglutide doses ten times lower than standard, supposedly taken for 'longevity' or 'mild appetite suppression without side effects.' The problem is that none of semaglutide's registration trials tested such doses for such indications — and the available dose-response data actually suggest the opposite.